GlassScriptPhysician profile
Munir Y Elawar
NPI 1497861447
$42,213.77
in general payments reported to CMS, 2019-2025
48 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $3,439 · 2021: $19K · 2022: $5,699 · 2024: $43.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $43.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $43.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $13,521.01 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $11,602.65 | 2021 | |
| Abbvie INC. | $7,340.36 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $1,249.31 | 2022 | |
| Biogen, INC. | $1,072.12 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $872.06 | 2019-2021 | |
| Allergan, INC. | $794.65 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $750.62 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $425.66 | 2019-2021 | |
| Ucb, INC. | $405.40 | 2019-2022 | |
| Lilly USA, LLC | $338.96 | 2019-2022 | |
| Lundbeck LLC | $262.50 | 2019-2021 | |
| Genzyme Corporation | $255.47 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $244.63 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $229.68 | 2019-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Munir Elawar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.